Patents Assigned to Centocor, Inc.
  • METHODS OF TREATING INFLAMMATION ASSOCIATED WITH VIRAL INFECTION WITH ANTI-TNF ANTIBODIES
    Publication number: 20070009524
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: January 10, 2002
    Publication date: January 11, 2007
    Applicants: New York University Medical Center, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • DNA encoding anti-TNF antibodies and peptides
    Patent number: 7160995
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: July 22, 2002
    Date of Patent: January 9, 2007
    Assignees: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods of inhibiting TNF-? in patients with Crohn's disease
    Patent number: 7160543
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: December 8, 2005
    Date of Patent: January 9, 2007
    Assignees: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Method of treating psoriasis using human anti-TNF antibodies and fragments
    Patent number: 7160542
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: January 9, 2007
    Assignees: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods of treating rheumatoid arthritis with anti-TNF antibodies
    Patent number: 7138118
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: December 8, 2005
    Date of Patent: November 21, 2006
    Assignees: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods of treating disseminated intravascular coagulation using anti-TNF antibodies
    Patent number: 7135178
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful for therapy of TNF?-mediated pathologies and conditions, including vascular inflammatory pathologies.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: November 14, 2006
    Assignees: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods for treating sarcoidosis using anti-TNF antibodies and fragments thereof
    Patent number: 7135179
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: July 13, 2005
    Date of Patent: November 14, 2006
    Assignees: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods of treating crohn's disease with anti-TNF antibodies
    Patent number: 7128907
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: March 4, 2003
    Date of Patent: October 31, 2006
    Assignees: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods for treating systemic lupus erythematosus using anti-TNF antibodies and fragments thereof
    Patent number: 7128908
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: July 12, 2005
    Date of Patent: October 31, 2006
    Assignees: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Anti-idiotypic anti-TNF antibodies and related immunoassay methods
    Patent number: 7101674
    Abstract: Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.
    Type: Grant
    Filed: July 2, 2001
    Date of Patent: September 5, 2006
    Assignees: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight, Scott A. Siegel
  • Erythropoietin conjugate compounds with extended half-lives
    Patent number: 7074755
    Abstract: The invention provides biologically active erythropoietin (EPO) conjugate compositions wherein EPO is covalently conjugated to a non-antigenic hydrophilic polymer covalently linked to an organic molecule that increases the circulating serum half-life of the composition. The invention thus relates to EPO derivatives described by the formula EPO-(X-Y)N where EPO is erythropoietin or its pharmaceutical acceptable derivatives having biological properties of causing bone marrow cells to increase production of reticulocytes and red blood cells, X is PEG or other water soluble polymers, Y is an organic molecule that increases the circulating half-life of the construct more than the PEG alone and N is an integer from 1 to 15. Other molecules may be included between EPO and X and between X and Y to provide the proper functionality for coupling or valency.
    Type: Grant
    Filed: May 17, 2003
    Date of Patent: July 11, 2006
    Assignee: Centocor, Inc.
    Inventor: George Heavner
  • RSV proteins, antibodies, compositions, methods and uses
    Patent number: 7070786
    Abstract: The present invention relates to at least one novel RSV proteins, antibodies, including isolated nucleic acids that encode at least one RSV protein or antibody, RSV vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: June 6, 2003
    Date of Patent: July 4, 2006
    Assignee: Centocor, Inc.
    Inventor: Bernard Scallon
  • Recombinant A2-specific TNF? specific antibodies
    Patent number: 7070775
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: July 4, 2006
    Assignees: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Anti-TNF chimeric antibody fragments
    Publication number: 20060140946
    Abstract: Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.
    Type: Application
    Filed: June 2, 2005
    Publication date: June 29, 2006
    Applicants: Centocor, Inc.,, New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Chimeric immunoglobulin for CD4 receptors
    Patent number: 7037496
    Abstract: Chimeric antibodies for CD4 receptor comprising a variable or antigen binding region of a non-human origin specific for CD4 receptor and a constant region of human origin are disclosed. These antibodies are useful as therapeutic agents for auto-immune disorders.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: May 2, 2006
    Assignee: Centocor, Inc.
    Inventors: John Ghrayeb, David M. Knight, James E. Looney
  • Formation of novel erythropoietin conjugates using transglutaminase
    Patent number: 6995245
    Abstract: The invention provides biologically active erythropoietin (EPO) conjugate compositions wherein a transglutaminase reaction is employed to covalently and site specifically conjugate the EPO molecule to a non-antigenic hydrophilic polymer that can also be covalently linked to an organic molecule either of which modification increases the circulating serum half-life of the composition.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: February 7, 2006
    Assignee: Centocor, Inc.
    Inventor: Chadler Pool
  • Methods of treating TNFalpha-mediated tissue injury using anti-TNF antibodies and peptides
    Publication number: 20060024310
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: August 2, 2005
    Publication date: February 2, 2006
    Applicants: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Anti-TNF antibodies and peptides of human tumor necrosis factor
    Patent number: 6991791
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: January 18, 2001
    Date of Patent: January 31, 2006
    Assignees: New York University School of Medicine, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods for treating systemic lupus erythematosus using anti-TNF antibodies and fragments thereof
    Publication number: 20060018905
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: July 12, 2005
    Publication date: January 26, 2006
    Applicants: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods for treating sarcoidosis using anti-TNF antibodies and fragments thereof
    Publication number: 20060018906
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: July 13, 2005
    Publication date: January 26, 2006
    Applicants: Centocor, Inc.,, New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel